Stay updated on SBRT +/- Pembrolizumab in NSCLC Clinical Trial

Sign up to get notified when there's something new on the SBRT +/- Pembrolizumab in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the SBRT +/- Pembrolizumab in NSCLC Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    No Change Detected
  3. Check
    22 days ago
    Change Detected
    Summary
    The page revision updated from v3.4.3 to v3.5.0.
    Difference
    0.0%
    Check dated 2026-03-19T05:25:27.000Z thumbnail image
  4. Check
    29 days ago
    Change Detected
    Summary
    Revision: v3.4.3 has been added to the page. Revision: v3.4.2 has been removed.
    Difference
    0.0%
    Check dated 2026-03-12T02:20:40.000Z thumbnail image
  5. Check
    57 days ago
    Change Detected
    Summary
    Revision updated from v3.4.1 to v3.4.2 in the page history. This appears to be a minor site version update with no substantive changes to study data or navigation.
    Difference
    0.0%
    Check dated 2026-02-11T11:52:00.000Z thumbnail image
  6. Check
    64 days ago
    Change Detected
    Summary
    Revision: v3.4.1 was added to the history and Revision: v3.4.0 was removed.
    Difference
    0.0%
    Check dated 2026-02-04T10:27:17.000Z thumbnail image
  7. Check
    71 days ago
    Change Detected
    Summary
    Glossary visibility controls and color-coded highlights for additions and deletions were added to the study history page. Revision notes now show 'Revision: v3.4.0', and 'No FEAR Act Data' was removed.
    Difference
    0.2%
    Check dated 2026-01-28T06:16:16.000Z thumbnail image
  8. Check
    86 days ago
    Change Detected
    Summary
    Footer now shows Revision: v3.3.4, replacing v3.3.3.
    Difference
    0.0%
    Check dated 2026-01-14T02:51:30.000Z thumbnail image

Stay in the know with updates to SBRT +/- Pembrolizumab in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the SBRT +/- Pembrolizumab in NSCLC Clinical Trial page.